Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genomic Valley BiotechBOM:539206 +1.00%57 Interest Coverage is No Debt (1) as of Mar. 2026, which is 100% below its 10-year median of 97.11. GuruFocus rates BOM:539206 with a GF Score™ of 57/100 and a GF Value™ of ₹12.92 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 374 Biotechnology companies, Genomic Valley Biotech ranks better than 99.2% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Genomic Valley Biotech's
Operating Income
for the
three
months ended in Mar. 2026 was ₹0.02 Mil. Genomic Valley Biotech's Interest Expense for the
three
months ended in Mar. 2026 was ₹0.00 Mil.
Genomic Valley Biotech has no debt.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Genomic Valley Biotech Ltd has no debt.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Genomic Valley Biotech's Interest Coverage or its related term are showing as below:
BOM:539206'
s Interest Coverage Range Over the Past 10 Years
Min: 2.1 Med: 97.11 Max: No Debt
Current: No Debt
BOM:539206's Interest Coverage is ranked better than 99.2% of 374
companies
in the Biotechnology industry
Industry Median: 104.025
vs BOM:539206: No Debt
Genomic Valley Biotech (BOM:539206) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Genomic Valley Biotech Interest Coverage Related Terms
Genomic Valley Biotech Interest Coverage Historical Data
* Premium members only.
The historical data trend for Genomic Valley Biotech's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BOM:539206 vs VRTX, REGN, RVMD: Interest Coverage Comparison
For the Biotechnology subindustry, Genomic Valley Biotech's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomic Valley Biotech Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genomic Valley Biotech's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Genomic Valley Biotech's Interest Coverage falls into.
Genomic Valley Biotech Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of No Debt <sup>(1)</sup> mean?
Genomic Valley Biotech (BOM:539206) has a Interest Coverage of No Debt (1) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Genomic Valley Biotech and its competitors. This is 99% below median its historical median of 97.11. Over the past decade, Genomic Valley Biotech's Interest Coverage has ranged from 2.10 to 10,000.00. According to the industry distribution chart, Genomic Valley Biotech ranks #3 out of 374 companies in the Biotechnology industry, placing it in the top 0.8%.
Is Genomic Valley Biotech's Interest Coverage too high?
Genomic Valley Biotech's current Interest Coverage of No Debt (1) is 99% below median its 10-year median of 97.11. Over the past 10 years, this metric has ranged from a low of 2.10 to a high of 10,000.00. Based on the distribution chart, Genomic Valley Biotech ranks #3 out of 374 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genomic Valley Biotech has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genomic Valley Biotech's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genomic Valley Biotech ranks #3 out of 374 companies for Interest Coverage. This places Genomic Valley Biotech in the top 1% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 104.03. Historically, Genomic Valley Biotech's own Interest Coverage has ranged from 2.10 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 104.03, based on 374 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Genomic Valley Biotech and its competitors. For the Biotechnology industry, the median Interest Coverage is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomic Valley Biotech's current Interest Coverage is No Debt (1), which is 99% below median its own 10-year median of 97.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomic Valley Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genomic Valley Biotech (BOM:539206) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹12.92, compared to a current price of ₹29.29 — trading 126.7% above its estimated fair value. The current Interest Coverage is No Debt (1), which is 99% below median its 10-year median of 97.11. Genomic Valley Biotech's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Genomic Valley Biotech (BOM:539206), the current Interest Coverage is No Debt (1) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomic Valley Biotech (BOM:539206) Overvalued in 2026?
Based on GuruFocus' analysis, Genomic Valley Biotech stock appears to be overvalued.
The current stock price of ₹29.29 is trading 126.7% above its estimated GF Value™ of ₹12.92.
GuruFocus considers Genomic Valley Biotech to be Significantly Overvalued.
Key valuation signals for BOM:539206:
Interest Coverage: No Debt (1) (99% below median its 10-year median of 97.11)
GF Value™: ₹12.92 vs. price of ₹29.29 (126.7% above fair value)
No single metric tells the full story. See the BOM:539206 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomic Valley Biotech Ltd is an India-based biotechnology company operating in the fields of genomics, molecular diagnostics, and AI-driven healthcare. The Company provides Next-Generation Sequencing (NGS) based diagnostic services, oncology diagnostics, personalized healthcare solutions, genetic disease risk assessment, community genomic screening, and research process outsourcing services. Its business is mainly segmented into diagnostic services and research services, with a focus on genomics, bioinformatics, and AI-enabled data analysis. The Company operates mainly in India, while also serving international researchers and collaborators.
57GF Score
Get the complete analysis for BOM:539206
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539206 has been successfully added to your 
